- Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before
study day 1
- Have sufficient symptoms to require anxiolytic drug therapy
- Have a score ≥4 on the Clinical Global Impressions Scale (CGI) severity of illness
item at screening and baseline
- Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine
- History or presence of any clinically important hepatic, renal, or other medical
disease that might compromise the study or be detrimental to the patient (eg,
clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
cell epithelioma], uncontrolled hypertension)
- Clinically important abnormality on screening physical examination, vital signs,
electrocardiogram (ECG), laboratory tests or urine drug screen